Investor Relations

Press Releases

Date Title and Summary View
Feb 24, 2016

Andrew Schiff, M.D. to Step Down From the Board

Feb 16, 2016

Presentation Scheduled on Tuesday, February 23, 2016 at 8:00 AM ET 

Feb 04, 2016
PRINCETON, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the underwriters of its previously announced
Jan 22, 2016
PRINCETON, N.J., Jan. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its underwritten public offering
Jan 21, 2016
PRINCETON, N.J., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that it intends to offer and sell $30 million of
Jan 15, 2016

Presentation Scheduled on Monday, January 18, 2016 at 11:30 AM ET

Dec 01, 2015
PRINCETON, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has received net proceeds of approximately $6 million in
Nov 17, 2015
PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive
Nov 09, 2015

Completion of the SECURE Clinical Trial for Twirla® Planned for Second Half of 2016; Resubmission to the FDA Planned for the First Half of 2017

Oct 19, 2015

Company Plans to Complete Clinical Trial in the Second Half of 2016 and File its Resubmission to the FDA in First Half of 2017